Fact checked byChristine Klimanskis, ELS

Read more

May 04, 2023
1 min read
Save

Endpoints met in phase 2a trial of AB-101a for pediatric atopic dermatitis

Fact checked byChristine Klimanskis, ELS
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Key takeaways:

  • AB-101a improved mild to moderate atopic dermatitis in pediatric patients as young as 2 years old.
  • All primary and secondary efficacy endpoints were met in the phase 2a trial.

Alphyn Biologics reported positive results for topical AB-101a in a phase 2a clinical trial in pediatric patients with mild to moderate atopic dermatitis.

“We are extremely pleased with the pediatric results,” Neal Koller, CEO of Alphyn, said in a press release. “The improvements these children experienced in the severity of disease and symptoms are particularly remarkable. AD can be a lifelong chronic disease, and options are needed for long-term continuous use.”

Generic Industry News infographic
Alphyn Biologics reported positive results for topical AB-101a in a phase 2a clinical trial in pediatric patients with mild to moderate atopic dermatitis.

The randomized double-blind study evaluating AB-101a, a novel topical candidate developed to treat immune and bacterial components of AD, met all primary and secondary efficacy endpoints while maintaining a positive safety profile.

Twenty-seven participants in the study were between the ages of 2 and 17 years old. After 4 weeks of treatment, approximately 52% of those who received AB-101a achieved IGA score improvement compared with 0% of those who received vehicle control.

Key secondary endpoints were also met. Approximately 35% of those who received AB-101a- achieved EASI 75 compared with 0% who received vehicle. Additionally, 32% had an improvement in body surface area, and 62% had an itch score improvement of at least 4.

No serious adverse events were reported. Adverse events for AB-101a included mild transient stinging in three participants.

The company plans to initiate a phase 2b trial in the U.S., Europe, Canada and Australia.

Reference: